PARP1 and non-small cell lung carcinoma: SCLC cells show increased levels of PARP-1 expression compared with NSCLC cells, and are significantly more sensitive to PARP-1 inhibition, suggesting that PARP-1 is a valid therapeutic target in SCLC [6].